ADVERSE EVENTS IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING LIPOSOMAL IRINOTECAN: UNDERSTANDING THE OCCURRENCE AND HOW MANAGEMENT AFFECTS PATIENT OUTCOMES

被引：0
|
作者：
Jameson, Gayle [1 ]
Caldwell, Lana [1 ]
Mirakhur, Beloo [2 ]
de Jong, Floris [3 ]
Ansaldo, Karen [1 ]
机构：
[1] HonorHealth, Scottsdale, AZ USA
[2] Ipsen Biopharmaceut, Basking Ridge, NJ USA
[3] Shire GmbH, Zug, Switzerland
来源：
ONCOLOGY NURSING FORUM | 2018年 / 45卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS-15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
    Woo, Wonhee
    Carey, Edward T.
    Choi, Minsig
    ONCOTARGETS AND THERAPY, 2019, 12 : 1455 - 1463
  • [2] Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
    Hubner, Richard A.
    Cubillo, Antonio
    Blanc, Jean-Frederic
    Melisi, Davide
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Becker, Claus
    Mamlouk, Khalid
    Belanger, Bruce
    Yang, Yoojung
    de Jong, Floris A.
    Siveke, Jens T.
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 24 - 33
  • [3] Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
    Yu, Kenneth H.
    Hendifar, Andrew E.
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala
    Cockrum, Paul
    Bhak, Rachel H.
    Nguyen, Catherine
    DerSarkissian, Maral
    Duh, Mei Sheng
    Bahary, Nathan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Adverse Events in Pediatric Cancer Patients Receiving Sorafenib or Sorafenib Plus Irinotecan
    Yokosuka, Tomoko
    Nakamura, Wataru
    Hayashi, Akiko
    Fujita, Sachio
    Miyagawa, Naoyuki
    Iwasaki, Fuminori
    Hamanoue, Satoshi
    Goto, Shoko
    Goto, Hiroaki
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S90 - S90
  • [5] Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nalIRI) in the US.
    Barzi, Afsaneh
    Miksad, Rebecca
    Surinach, Andy
    Corvino, Frank A.
    Wang, Siqi
    Torres, Aracelis Z.
    Mamlouk, Khalid Kevin
    Pulgar, Sonia J.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer
    Brendel, Karl
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Dean, Andrew
    Macarulla, Teresa
    Maxwell, Fiona
    Mody, Kabir
    Pedret-Dunn, Anna
    Wainberg, Zev A.
    Zhang, Bin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (12): : 1550 - 1563
  • [7] Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
    Barzi, Afsaneh
    Miksad, Rebecca
    Surinach, Andy
    Corvino, Frank A.
    Wang, Siqi
    Torres, Aracelis Z.
    Mamlouk, Khalid
    Pulgar, Sonia
    Valderrama, Adriana
    Bekaii-Saab, Tanios
    Ahn, Daniel
    PANCREAS, 2020, 49 (02) : 193 - 200
  • [8] Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients
    Riera, Pau
    Paez, David
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (10) : 1157 - 1163
  • [9] Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients
    O'Reilly, Eileen Mary
    Surinach, Andy
    Dillon, Allison
    Cockrum, Paul
    Yu, Kenneth H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
    Abushahin, Laith, I
    Cockrum, Paul
    Surinach, Andy
    Belanger, Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345